Clinical trials: Early Breast Cancer, open to volunteers
Breast Cancer
Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer
This is a pilot, prospective, interventional, monocentric study designed to evaluate, in a real-life situation, adherence to tamoxifen treatment as a function of the taking of alternative and complementary therapies in patients…
- Trial name
- EUTACAM (NCT04740697)
- Testing
- Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Institut Claudius Regaud
HER2-positive Breast Cancer
Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer
Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a molecular subtype with high malignancy and high risk to recurrence and metastasis.
- Trial name
- NeraHER2 (NCT06693024)
- Testing
- neratinib
- Where
- China
- Volunteers
- 2,806 people
- Sponsor
- Shu Wang
Breast Cancer, Breast Cancer (Early Breast Cancer)
Luminal Breast Cancer Cryoablation
LUBRECA will evaluate the safety and efficacy of cryoablation with liquid nitrogen to treat cT1cN0 luminal breast cancer diagnosed in postmenopausal women
- Trial name
- LUBRECA (NCT07447414)
- Testing
- Cryoablation with liquid nitrogen (Prosense® system)
- Where
- Spain
- Volunteers
- 140 people
- Sponsor
- Lucía Graña López
Breast Cancer
Clinical and Biological Study of Early-onset Breast Cancer and the Influence of the Reproductive Cycle on the Aggressiveness of the Disease
The incidence of breast cancer is increasing, particularly among young women. Cancers in young women are associated with a poor prognosis. The causes remain poorly understood.
- Trial name
- ARTEMIS (NCT07601152)
- Testing
- No Intervention: Observational Cohort
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Institut Cancerologie de l'Ouest
Breast Cancer, Molecular Pathway Deregulation
Study of Molecular Characterisation of Early Operable Primary Breast Cancer in Pakistani Population
This study is looking at the biological characteristics of early operable primary breast cancer in Pakistani Population by using IHC
- Conditions
- Breast Cancer, Molecular Pathway Deregulation, Treatment
- Trial name
- BrCa (NCT06830590)
- Testing
- Molecular characterisation
- Where
- Pakistan
- Volunteers
- 300 people
- Sponsor
- Liaquat University of Medical & Health Sciences
Breast Cancer
Financial Toxicity in Patients With Early-stage Breast Cancer
Non-profit, multicenter, prospective, observational study. This study aims to evaluate whether the articulated treatment algorithm that is now possible for early-stage breast cancer patients does produce tangible changes of…
- Trial name
- VOICE - GIM36 (NCT07354165)
- Testing
- Questionnaires
- Where
- Italy
- Volunteers
- 864 people
- Sponsor
- National Cancer Institute, Naples
Breast Cancer
Three-Dimensional Ultrasound and Spectroscopy as Early Indicators of Breast Cancer Response to Neoadjuvant Treatment
The purpose of the study is to test the hypothesis that ultrasound imaging and spectroscopy may be used as a predictive marker of advanced tumour response to neoadjuvant treatment consisting of chemotherapy or concurrent…
- Trial name
- NCT06193122
- Testing
- Ultrasound imaging 3D and Spectroscopy
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Sunnybrook Health Sciences Centre
HER2-positive Breast Cancer
Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy
Chemotherapy combined with trastuzumab and patuzumab is the standard neoadjuvant therapy for HER2 positive breast cancer patients.
- Trial name
- nonPHER (NCT06693037)
- Where
- China
- Volunteers
- 2,092 people
- Sponsor
- Shu Wang
HER2-positive Breast Cancer
Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy
Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a molecular subtype with high malignancy and easy recurrence and metastasis.
- Trial name
- TaxDHER2 (NCT06711068)
- Where
- China
- Volunteers
- 8,077 people
- Sponsor
- Shu Wang
Breast Cancer Invasive
Ultrasound Imaging, Spectroscopy and Ultrasound Imaging of Vascular Blood Flow as Early Indicators of Breast Cancer Response to Neoadjuvant Treatment.
We have previously demonstrated that high-frequency ultrasound and spectroscopy, and recently conventional-frequency ultrasound and spectroscopy may be used to detect cell death in vitro, in situ and in vivo.
- Trial name
- NCT00437879
- Where
- Canada
- Volunteers
- 600 people
- Sponsor
- Sunnybrook Health Sciences Centre
Breast Cancer Early Stage Breast Cancer (Stage 1-3), SBRT
A Phase I Dose-escalation Trial of Definitive Single Dose Stereotactic Body Radiotherapy in Low-risk Breast Cancer Patients: DESERT I Trial
Radiotherapy (RT) is a fundamental pillar in the fight against cancer. In the case of breast cancer, RT has traditionally been applied as an adjuvant treatment following surgery.
- Trial name
- DESERT-I (NCT06671691)
- Testing
- SBRT level I, SBRT level II, SBRT level III
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Universitat de les Illes Balears
Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8, Anatomic Stage II Breast Cancer AJCC v8
Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
This phase II trial tests how well fisetin and exercise works in preventing frailty in breast cancer survivors. Fisetin is a natural substance found in strawberries and other foods and is available as a nutritional supplement.
- Conditions
- Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Breast Carcinoma
- Trial name
- PROFFi (NCT06113016)
- Testing
- Biospecimen Collection, Educational Intervention, Exercise Intervention
- Where
- 6 sites in United States
- Volunteers
- 164 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Neoplasms
A Prospective Study of Preoperative Tumor-bed Boost Followed by Oncoplastic Surgery and Adjuvant Whole Breast Radiotherapy for Early Stage Breast Cancer (BIRKIN)
This study explores the feasibility of preoperative single-dose tumor-bed boost followed by oncoplastic breast-conserving surgery and ultra-hypofractionated postoperative radiotherapy in patients with early stage breast cancer.
- Trial name
- BIRKIN (NCT05603078)
- Testing
- Preoperative MRI-guided tumor-bed boost and postopreative ultra-hypofractionated radiotherapy (26 Gy/5.2Gy/5)
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer Females
A Real-world Study on the Compliance of OFS-assisted Endocrine Therapy for Hormone Receptor-positive(HR+) Premenopausal Breast Cancer
The goal of this observational study is to observe the long-term prognosis of patients with early HR-positive premenopausal breast cancer.
- Trial name
- NCT07180914
- Volunteers
- 300 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Adjuvant Treatment in Premenopausal Breast Cancer
Multicentric retroprospective observational study to collect outcome in premenopausal breast cancer patients who undergone the 21-multigene assay Oncotype DX from 1st January 2013 to 31st December 2022 and adjuvant treatment.
- Trial name
- PERSEVEREX (NCT06807749)
- Where
- 2 sites in Italy
- Volunteers
- 800 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
HER2-positive Breast Cancer
Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer
Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a molecular subtype with high malignancy and easy recurrence and metastasis.
- Trial name
- TaxCbHER2 (NCT06722612)
- Where
- China
- Volunteers
- 2,916 people
- Sponsor
- Shu Wang
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Outcomes of a Novel Technique Minimal Scar Mastectomy
Nipple sparing mastectomy is oncologically safe and has a good cosmetic outcome. However, nipple sparing mastectomy was conventionally performed with reconstruction.
- Trial name
- NCT06676761
- Testing
- nipple sparing mastectomy without reconstruction
- Where
- 2 sites in Singapore
- Volunteers
- 100 people
- Sponsor
- KK Women's and Children's Hospital
Hereditary Cancer Syndrome
CfDNA in Hereditary And High-risk Malignancies 2
The goal of this study is to understand the performance of an experimental blood test that aims to detect early tumors in patients with hereditary cancer syndromes.
- Trial name
- CHARM2 (NCT06726642)
- Testing
- Cell-free DNA analysis
- Where
- 8 sites in Canada
- Volunteers
- 1,000 people
- Sponsor
- University Health Network, Toronto
HR+/HER2- Early Breast Cancer
IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE
The goal of this interventional study is to evaluate the effect of standardized patient coaching on treatment adherence among patients taking abemaciclib.
- Trial name
- IMPACT PT (NCT07521202)
- Testing
- Standardized patient coaching
- Where
- 8 sites in Germany
- Volunteers
- 257 people
- Sponsor
- Institut fuer Frauengesundheit